RiTdisplay announced its official entry into the medical CDMO (Contract Development & Manufacturing Organization) services sector. The company is partnering with the UK-based Adtec Healthcare and Taiwan’s SG Biomedical to develop a low-temperature plasma medical platform. It is also collaborating with an international gene sequencing team and with LIPO Biotech on optical genomics applications. RiTdisplay stated that this marks a key milestone in its biomedical transformation—transitioning from optoelectronics manufacturing into the high–value-added medical industry and opening its second growth curve.
Low-temperature plasma therapy for chronic wounds offers several clinical advantages: low heat, safety, painless and noncontact treatment, and no side effects. It has obtained dual certification from the EU CE and Taiwan’s TFDA, supported by over 15 years of clinical evidence in Europe and 65 peer-reviewed journal publications. It is widely recognized by the global medical community as an innovative wound treatment modality.
Leveraging its long-standing expertise in optoelectronics and precision manufacturing, RiTdisplay is investing in this clinically validated low-temperature plasma wound care technology. The technology was jointly developed by Adtec Healthcare in the UK and the Max Planck Institute in Germany, with SG Biomedical responsible for clinical introduction and market expansion in Asia. In 2025, SG Biomedical completed a strategic integration with Adtec’s major shareholder fund and now holds a 16.8% stake in Adtec, forming a close technological and capital alliance to advance global adoption of low-temperature plasma and establish an Asian manufacturing base.
Through a strategic investment in SG Biomedical in 2025, RiTdisplay became its core partner in medical manufacturing. The two companies are combining clinical demand, manufacturing capacity, and international market access to build the “Asian Low-Temperature Plasma Medical Manufacturing Platform,” establishing a complete ecosystem spanning technology development, mass production, and clinical validation. Adtec Healthcare currently manufactures the full device system, but a portion of the production process will be transferred into RiTdisplay’s manufacturing operations in the second quarter of 2026, with full-system mass production targeted to begin in the fourth quarter. This platform marks RiTdisplay’s official entry into high–value-added medical manufacturing.
As of September this year, the low-temperature plasma wound treatment system has been adopted by seven leading medical centers and major hospitals across northern, central, and southern Taiwan, indicating that the technology has reached the highest tier of Taiwan’s clinical healthcare applications. Beginning in 2026, RiTdisplay and SG Biomedical will continue a second-phase medical center expansion plan, aiming to extend deployment to 26 medical centers across Taiwan by the end of 2026, while simultaneously expanding into Southeast Asian markets.
Resource: 錸寶跨入生醫產業 低溫電漿平台領跑醫療製造
